Skip to main content

Advertisement

SpringerLink
Log in

Highly sensitive detection of melanoma based on serum proteomic profiling

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

There is no available tumor marker that can detect primary melanoma. Proteomics analysis has been proposed as a novel tool that would lead to the discovery of potential new tumor markers.

Methods

We developed a serum proteomic fingerprinting approach coupled with a classification method to determine whether proteomic profiling could discriminate between melanoma and healthy volunteers. A total of 108 serum samples from 30 early-stage [American Joint Committee on Cancer (AJCC) stage I or II] and 30 advanced-stage (AJCC stage III or IV) melanoma patients and 48 healthy volunteers were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) utilizing protein chip technology and artificial neural networks.

Results

In a first step, a multiprotein classifier was built using a training set of 30 pathologically confirmed melanoma and 24 healthy volunteer serum samples, resulting in good classification accuracy for correct diagnosis and stage classification assignment. Subsequently, our multiprotein classifier was tested in an independent validation set of 30 melanoma and 24 non-cancer serum samples patients, maintained in a good diagnostic accuracy of 98.1% (sensitivity 96.7%, specificity 100%), and 100% stage I/II classification assignment.

Conclusions

Although results remain to be confirmed in larger collective patient cohorts, we could demonstrate the usefulness of proteomic profiling as a sensitive and specific assay to detect melanoma, including non-metastatic melanoma, from the serum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):3635–3648

    PubMed  CAS  Google Scholar 

  • Brennecke S, Deichmann M, Naeher H, Kurzen H (2005) Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res 15(6):515–522. doi:10.1097/00008390-200512000-00006

    Article  PubMed  CAS  Google Scholar 

  • Caputo E, Lombardi ML, Luongo V, Moharram R, Tornatore P, Pirozzi G, Guardiola J, Martin BM (2005) Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques. J Chromatogr B Analyt Technol Biomed Life Sci 819(1):59–66. doi:10.1016/j.jchromb.2005.01.022

    Article  PubMed  CAS  Google Scholar 

  • Cazares LH, Diaz JI, Drake RR, Semmes OJ (2008) MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers. Methods Mol Biol 428:125–140. doi:10.1007/978-1-59745-117-8_7

    Article  PubMed  CAS  Google Scholar 

  • Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, Naher H (1999) S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on cancer stage IV melanoma. J Clin Oncol 17(6):1891–1896

    PubMed  CAS  Google Scholar 

  • Fung ET, Wright GL Jr, Dalmasso EA (2000) Proteomic strategies for biomarker identification: progress and challenges. Curr Opin Mol Ther 2(6):643–650

    PubMed  CAS  Google Scholar 

  • Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B (2003) Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97(7):1737–1745. doi:10.1002/cncr.11250

    Article  PubMed  CAS  Google Scholar 

  • Girosi F (1998) An equivalence between sparse approximation and support vector machines. Neural Comput 10(6):1455–1480. doi:10.1162/089976698300017269

    Article  PubMed  Google Scholar 

  • Harpio R, Einarsson R (2004) S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 37(7):512–518. doi:10.1016/j.clinbiochem.2004.05.012

    Article  PubMed  CAS  Google Scholar 

  • Kageshita T, Yoshii A, Kimura T, Kuriya N, Ono T, Tsujisaki M, Imai K, Ferrone S (1993) Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res 53(20):4927–4932

    PubMed  CAS  Google Scholar 

  • Lee ML, Lu W, Whitmore GA, Beier D (2002) Models for microarray gene expression data. J Biopharm Stat 12(1):1–19. doi:10.1081/BIP-120005737

    Article  PubMed  Google Scholar 

  • Li L, Tang H, Wu Z, Gong J, Gruidl M, Zou J, Tockman M, Clark RA (2004) Data mining techniques for cancer detection using serum proteomic profiling. Artif Intell Med 32(2):71–83. doi:10.1016/j.artmed.2004.03.006

    Article  PubMed  Google Scholar 

  • Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D (2005) Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 23(22):5088–5093. doi:10.1200/JCO.2005.03.164

    Article  PubMed  CAS  Google Scholar 

  • Moller T, Anderson H, Aareleid T, Hakulinen T, Storm H, Tryggvadottir L, Corazziari I, Mugno E (2003) Cancer prevalence in Northern Europe: the EUROPREVAL study. Ann Oncol 14(6):946–957. doi:10.1093/annonc/mdg255

    Article  PubMed  CAS  Google Scholar 

  • Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306):572–577. doi:10.1016/S0140-6736(02)07746-2

    Article  PubMed  CAS  Google Scholar 

  • Rai AJ, Stemmer PM, Zhang Z, Adam BL, Morgan WT, Caffrey RE, Podust VN, Patel M, Lim LY, Shipulina NV, Chan DW, Semmes OJ, Leung HC (2005) Analysis of human proteome organization plasma proteome project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 5(13):3467–3474. doi:10.1002/pmic.200401320

    Article  PubMed  CAS  Google Scholar 

  • Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L (2005) Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 51(1):102–112. doi:10.1373/clinchem.2004.038950

    Article  PubMed  CAS  Google Scholar 

  • Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN (1993) Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 72(10):3091–3098. doi:10.1002/1097-0142(19931115)72:10<3091::AID-CNCR2820721034>3.0.CO;2-V

    Article  PubMed  CAS  Google Scholar 

  • Solassol J, Marin P, Demettre E, Rouanet P, Bockaert J, Maudelonde T, Mange A (2005) Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection. Anal Biochem 338(1):26–31. doi:10.1016/j.ab.2004.11.031

    Article  PubMed  CAS  Google Scholar 

  • Solassol J, Jacot W, Lhermitte L, Boulle N, Maudelonde T, Mange A (2006) Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Rev Proteomics 3(3):311–320. doi:10.1586/14789450.3.3.311

    Article  PubMed  CAS  Google Scholar 

  • Stahlecker J, Gauger A, Bosserhoff A, Buttner R, Ring J, Hein R (2000) MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res 20(6D):5041–5044

    Google Scholar 

  • Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19(2):577–583

    PubMed  CAS  Google Scholar 

  • Wakamatsu K, Kageshita T, Furue M, Hatta N, Kiyohara Y, Nakayama J, Ono T, Saida T, Takata M, Tsuchida T, Uhara H, Yamamoto A, Yamazaki N, Naito A, Ito S (2002) Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years’ experience. Melanoma Res 12(3):245–253. doi:10.1097/00008390-200206000-00008

    Article  PubMed  CAS  Google Scholar 

  • Wilson LL, Tran L, Morton DL, Hoon DS (2004) Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Ann NY Acad Sci 1022:317–322. doi:10.1196/annals.1318.047

    Article  PubMed  CAS  Google Scholar 

  • Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC Jr (2007) Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 107(3):526–531. doi:10.1016/j.ygyno.2007.08.009

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

We thank Pr. G. Favre and Dr. C. Allal for the use of the PBSIIc ProteinChip reader

Author information

Authors and Affiliations

  1. Department of Dermatology, CHU Montpellier, Hôpital Saint Eloi, Montpellier, France

    Julie Caron & Bernard Guillot

  2. Department of Cellular Biology, CHU Montpellier, Hôpital Arnaud de Villeneuve, 371 Avenue du Doyen Giraud, 34295, Montpellier Cedex 5, France

    Alain Mangé & Jérôme Solassol

  3. University of Montpellier I, Montpellier, France

    Julie Caron, Alain Mangé, Bernard Guillot & Jérôme Solassol

  4. Department of Clinical Oncoproteomic, Val d’Aurelle Cancer Institute, Montpellier, France

    Alain Mangé & Jérôme Solassol

Authors
  1. Julie Caron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alain Mangé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernard Guillot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jérôme Solassol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jérôme Solassol.

Additional information

J. Caron and A. Mangé contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caron, J., Mangé, A., Guillot, B. et al. Highly sensitive detection of melanoma based on serum proteomic profiling. J Cancer Res Clin Oncol 135, 1257–1264 (2009). https://doi.org/10.1007/s00432-009-0567-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-009-0567-7

Keywords

Search

Navigation